CAR-T (Allogeneic)
Memory NK (Allogeneic)
-- Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance --…
-- Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer -- ST. LOUIS, MO and SAN DIEGO, CA, March…
-- WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors -- --WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,…
Wugen is a clinical-stage biotechnology company
Cellular therapies originating from healthy donors
Come join our growing teams in San Diego and St. Louis